Chai Discovery develops AI-powered drug discovery platforms to accelerate pharmaceutical research and development.
$400MSeries C
A $400M Series C for drug discovery AI signals that enterprise biotech is finally willing to bet real capital on AI-assisted workflows—not just hype. At this stage and size, Chai is likely scaling compute infrastructure, hiring domain experts to validate model outputs, and building integrations into pharma workflows (the hard part). If you're building B2B tools for regulated industries, watch how they handle the liability/validation problem—that's the actual moat, not the model.